Suven Pharmaceuticals Ltd.
-
NSE: SUVENPHAR
-
BSE: 543064
-
Q
-
V
-
T
Quality Score
High Financial StrengthValuation Score
Expensive ValuationTechnical Score
Technically Moderately BullishBroker average target upside %
8.20 %
Below industry Median
TTM PE Ratio
29.60
Above industry Median
Price to Book Ratio
7.00
High in industry
Operating Revenues Qtr Cr
369.40 Cr
Above industry Median
Net Profit Qtr Cr
124.00 Cr
High in industry
RSI
57.30
RSI is mid-range
MFI
65.60
MFI is mid-range
MACD
1.10
MACD above Signal and Center
MACD Signal Line
0.90
MACD above Signal and Center
30Day SMA Rs
474.10 Rs
Price above SMA 474.11
50Day SMA Rs
472.10 Rs
Price above SMA 472.09
100Day SMA Rs
478.90 Rs
Price below SMA-100
200Day SMA Rs
466.30 Rs
Price above SMA 466.34
Promoter holding %
60.00
No change in Promoter holding
FII holding current Qtr %
9.47
FII holdings rise by 1.36%
MF holding current Qtr %
8.56
MF holdings fell by 0.41%
Institutions holding %
20.90
Institutions holding increased by 1.4300%.
Broker Average Rating
3.00
Broker Average Rating
Broker Covering stock
2.00
2 Broker Covering stock
Broker 1Year total
2.00
2 Broker 1Year total
Broker 6M Reco downgrade
0.00
0 Broker 6M Reco downgrade
Broker 6M Reco upgrade
0.00
0 Broker 6M Reco upgrade
Broker 6M Target downgrade
1.00
1 Broker 6M Target downgrade
Broker 6M Target upgrade
0.00
0 Broker 6M Target upgrade
Momentum score
61.41
Technically Moderately Bullish
Valuation score
19.83
Expensive Valuation
Quality score
58.86
High Financial Strength
-
- 2023-06-02T05:43:47+00:00
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and year ended March 31, 2023 conducted after the meeting of Board of Directors held on May 25, 2023. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
Read More -
- 2023-05-26T14:36:17+00:00
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated May 19, 2023, that audio recording of the conference call for the quarter and year ended March 31, 2023 held on Friday, May 26, 2023, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.
Read More -
- 2023-05-26T09:16:49+00:00
Suven Pharmaceuticals Results Earnings Call for Q4FY23
Conference Call with Suven Pharmaceuticals Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Read More -
- 2023-05-26T08:16:02+00:00
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and year ended March 31, 2023. The advertisements as appeared today i.e. May 26, 2023 in Andhra Prabha (Telugu) and Business Standard. The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements This is for your information and record.
Read More -
- 2023-05-26T05:20:48+00:00
Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to above subject, please find enclosed herewith the Annual Secretarial Compliance Report issued by Mrs. D. Renuka, Practicing Company Secretary, for the financial year ended 31st March, 2023, under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019 as amended from time to time. We request you to take this document on your record.
Read More -
- 2023-05-25T10:50:16+00:00
Suven Pharmaceuticals Ltd - 543064 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half-year ended 31st March, 2023. This is for your information and record.
Read More -
- 2023-05-25T08:11:20+00:00
Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting
With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 25, 2023, has taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors. Further, we are enclosing herewith the following documents: 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2023 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statement. 2) Auditor's Reports on the financial results as mentioned above 3) Declaration in respect of Audit Reports with unmodified opinion and 4) Earnings Presentation of our company to investors
Read More -
- 2023-05-25T07:28:45+00:00
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs
Read More -
- 2023-05-24T10:17:52+00:00
Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company has received intimation from the RTA (Registrar & Share Transfer Agent) i.e. Kfin Technologies Limited regarding loss of share certificate(s), details are as per letter attached below.
Read More -
- 2023-05-19T10:33:43+00:00
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Friday, May 26, 2023 at 12:00 Noon IST to discuss the Audited Financial Results for the Q4 & FY23, to be declared on May 25, 2023. This is for your information and record.
Read More -
- 2023-05-18T10:55:30+00:00
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Thursday, The 25Th May, 2023
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Thursday, the 25th May, 2023 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2023 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2023 as per PIT Code of the Company. Trading window will be opened from 29th May, 2023. You are requested to take this notice on your record.
Read More -
- 2023-04-18T12:01:16+00:00
Suven Pharmaceuticals Ltd - 543064 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySuven Pharmaceuticals Ltd 2CIN NO.L24299TG2018PLC128171 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 24.56 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: K HANUMANTHA RAO Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: khrao@suvenpharm.com Name of the Chief Financial Officer: P Subba Rao Designation: Chief FInancial Officer EmailId: psrao@suvenpharm.com Date: 18/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Read More -
- 2023-04-13T11:25:50+00:00
Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 40(10) For The Year Ended 31St March, 2023
With reference to above subject, please find enclosed Compliance Certificate for the year ended 31st March, 2023 issued by the Practicing Company Secretary, under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record.
Read More -
- 2023-04-11T11:39:58+00:00
Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended March 31, 2023. This is for your information and record.
Read More -
- 2023-04-11T11:34:04+00:00
Suven Pharmaceuticals Ltd - 543064 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2023
With reference to the above subject, please find enclosed compliance certificate for the year ended 31st March, 2023 duly signed by the Compliance Officer and authorised representative of the Share Transfer Agent (KFin Technologies Limited, Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record.
Read More -
- 2023-03-31T10:42:04+00:00
Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st April, 2023 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and year ending 31st March, 2023, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Read More -
- 2023-03-18T06:01:05+00:00
Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company has received intimation from shareholder of the Company, regarding loss of share certificate(s) as details mentioned below. An email request received from Shareholder is enclosed herewith.
Read More -
- 2023-03-09T12:16:26+00:00
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
Read More -
- 2023-03-09T12:15:19+00:00
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
Read More -
- 2023-03-09T12:14:10+00:00
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudharani Jasti
Read More
| Ex-date | Dividend Amount | Dividend Type | Record Date |
|---|
Bonus History
Adani Ports & Special Economic Zone Ltd. has not announced any bonus since Jan 1, 2000.
Check out stocks with top dividendAdani Ports & Special Economic Zone Ltd. has split the face value 1 time since Sept. 23, 2010. Adani Ports & Special Economic Zone Ltd. had last split the face value of its shares from Rs 10 to Rs 2 in 2016.The share has been quoting on an ex-split basis from Sept. 23, 2010.
| Ex-date | Old FV | New FV | Record Date |
|---|---|---|---|
| Sept. 23, 2010 | 10 | FINAL | Sept. 24, 2010 |